{ "id": "R42066", "type": "CRS Report", "typeId": "REPORTS", "number": "R42066", "active": true, "source": "EveryCRSReport.com, University of North Texas Libraries Government Documents Department", "versions": [ { "source": "EveryCRSReport.com", "id": 588620, "date": "2016-05-03", "retrieved": "2020-01-02T15:51:00.779269", "title": "Synthetic Drugs: Overview and Issues for Congress", "summary": "Synthetic drugs, as opposed to natural drugs, are chemically produced in a laboratory. Their chemical structure can be either identical to or different from naturally occurring drugs, and their effects are designed to mimic or even enhance those of natural drugs. When produced clandestinely, they are not typically controlled pharmaceutical substances intended for legitimate medical use. Designer drugs are a form of synthetic drugs. They contain slightly modified molecular structures of illegal or controlled substances, and they are modified in order to circumvent existing drug laws. While the issue of synthetic drugs and their abuse is not new, Congress has demonstrated a renewed concern with the issue. \nFrom 2009 to 2011, synthetic drug abuse was reported to have dramatically increased. During this time period, calls to poison control centers for incidents relating to harmful effects of synthetic cannabinoids (such as \u201cK2\u201d and \u201cSpice\u201d) and stimulants (such as \u201cbath salts\u201d) increased at what some considered to be an alarming rate. The number of hospital emergency department visits involving synthetic cannabinoids more than doubled from 2010 to 2011. In 2012 and 2013, however, the number of calls to poison control centers for incidents relating to harmful effects of synthetic cannabinoids and synthetic stimulants decreased. Calls regarding bath salts have declined each year since 2011, while calls regarding synthetic cannabinoids have increased since the drops in 2012 and 2013. The Monitoring the Future (MTF) survey results from 2015 indicate that annual prevalence rates for use of synthetic cannabinoids are down over the last two years while bath salt use remained low. Government and media reports indicate that fentanyl, a synthetic opioid 50-100 times stronger than morphine, is rising in popularity as well as various synthetic cannabinoids.\nThe reported harmful effects of synthetic substances range from nausea to drug-induced psychosis. Due to the unpredictable nature of synthetic drugs and of human consumption of these drugs, the true effects of many of these drugs are unknown. Many states have responded to synthetic drug abuse by passing laws banning certain synthetic cannabinoids and stimulants.\nIn 2011, the Attorney General\u2014through the Drug Enforcement Administration (DEA)\u2014used his temporary scheduling authority to place five synthetic cannabinoids and three synthetic stimulants on Schedule I of the Controlled Substances Act (CSA). Concern over the reported increase in use of certain synthetic cannabinoids and stimulants resulted in legislative action to schedule specific substances. The Synthetic Drug Abuse Prevention Act of 2012\u2014Subtitle D of Title XI of the Food and Drug Administration Safety and Innovation Act (P.L. 112-144)\u2014added five structural classes of substances in synthetic cannabinoids (and their analogues) as well as 11 synthetic stimulants and hallucinogens to Schedule I of the CSA. In addition, the act extended the DEA\u2019s authority to temporarily schedule substances. In April 2013, then-Attorney General Holder\u2014through the DEA and in consultation with the Department of Health and Human Services (HHS)\u2014took administrative action to permanently place methylone on Schedule I of the CSA. A number of administrative scheduling actions have since taken place. \nIn considering permanent placement of synthetic substances on Schedule I of the CSA, there are several issues on which Congress may deliberate. Policymakers may consider the implications on the federal criminal justice system of scheduling certain synthetic substances. Another issue is whether Congress should schedule certain synthetic substances or whether these substances merit Attorney General (in consultation with the Secretary of HHS) scheduling based on qualifications specified in the CSA. Congress may also consider whether placing additional synthetic drugs on Schedule I may hinder future medical research. In addition, policymakers may consider whether it is more efficient to place these drugs on Schedule I of the CSA or to treat them as analogue controlled substances under the Controlled Substances Analogue Enforcement Act. In considering enforcement challenges identified by the DEA, Congress may consider whether to amend the CSA to better facilitate enforcement action against the illicit synthetic drug market.", "type": "CRS Report", "typeId": "REPORTS", "active": true, "formats": [ { "format": "HTML", "encoding": "utf-8", "url": "https://www.crs.gov/Reports/R42066", "sha1": "be43ddcc02e2999449f7f55bb159e7f6922df6bb", "filename": "files/20160503_R42066_be43ddcc02e2999449f7f55bb159e7f6922df6bb.html", "images": { "/products/Getimages/?directory=R/html/R42066_files&id=/0.png": "files/20160503_R42066_images_bd09849452a11fc155a3cc2d01f2d49045baaa37.png" } }, { "format": "PDF", "encoding": null, "url": "https://www.crs.gov/Reports/pdf/R42066", "sha1": "1eba7b6c7d1aa72180052c62e2db2fc54276384c", "filename": "files/20160503_R42066_1eba7b6c7d1aa72180052c62e2db2fc54276384c.pdf", "images": {} } ], "topics": [ { "source": "IBCList", "id": 4793, "name": "Drug Control" } ] }, { "source": "EveryCRSReport.com", "id": 450160, "date": "2016-02-26", "retrieved": "2016-04-06T17:00:21.595020", "title": "Synthetic Drugs: Overview and Issues for Congress", "summary": "Synthetic drugs, as opposed to natural drugs, are chemically produced in a laboratory. Their chemical structure can be either identical to or different from naturally occurring drugs, and their effects are designed to mimic or even enhance those of natural drugs. When produced clandestinely, they are not typically controlled pharmaceutical substances intended for legitimate medical use. Designer drugs are a form of synthetic drugs. They contain slightly modified molecular structures of illegal or controlled substances, and they are modified in order to circumvent existing drug laws. While the issue of synthetic drugs and their abuse is not new, Congress has demonstrated a renewed concern with the issue. \nFrom 2009 to 2011, synthetic drug abuse was reported to have dramatically increased. During this time period, calls to poison control centers for incidents relating to harmful effects of synthetic cannabinoids (such as \u201cK2\u201d and \u201cSpice\u201d) and stimulants (such as \u201cbath salts\u201d) increased at what some considered to be an alarming rate. The number of hospital emergency department visits involving synthetic cannabinoids more than doubled from 2010 to 2011. In 2012 and 2013, however, the number of calls to poison control centers for incidents relating to harmful effects of synthetic cannabinoids and synthetic stimulants decreased. Calls regarding bath salts have declined each year since 2011, while calls regarding synthetic cannabinoids have increased since the drops in 2012 and 2013. The Monitoring the Future (MTF) survey results from 2015 indicate that annual prevalence rates for use of synthetic cannabinoids are down over the last two years while bath salt use remained low. Government and media reports indicate that fentanyl, a synthetic opioid 50-100 times stronger than morphine, is rising in popularity as well as various synthetic cannabinoids.\nThe reported harmful effects of synthetic substances range from nausea to drug-induced psychosis. Due to the unpredictable nature of synthetic drugs and of human consumption of these drugs, the true effects of many of these drugs are unknown. Many states have responded to synthetic drug abuse by passing laws banning certain synthetic cannabinoids and stimulants.\nIn 2011, the Attorney General\u2014through the Drug Enforcement Administration (DEA)\u2014used his temporary scheduling authority to place five synthetic cannabinoids and three synthetic stimulants on Schedule I of the Controlled Substances Act (CSA). Concern over the reported increase in use of certain synthetic cannabinoids and stimulants resulted in legislative action to schedule specific substances. The Synthetic Drug Abuse Prevention Act of 2012\u2014Subtitle D of Title XI of the Food and Drug Administration Safety and Innovation Act (P.L. 112-144)\u2014added five structural classes of substances in synthetic cannabinoids (and their analogues) as well as 11 synthetic stimulants and hallucinogens to Schedule I of the CSA. In addition, the act extended the DEA\u2019s authority to temporarily schedule substances. In April 2013, then-Attorney General Holder\u2014through the DEA and in consultation with the Department of Health and Human Services (HHS)\u2014took administrative action to permanently place methylone on Schedule I of the CSA. A number of administrative scheduling actions have since taken place. \nIn considering permanent placement of synthetic substances on Schedule I of the CSA, there are several issues on which Congress may deliberate. Policymakers may consider the implications on the federal criminal justice system of scheduling certain synthetic substances. Another issue is whether Congress should schedule certain synthetic substances or whether these substances merit Attorney General (in consultation with the Secretary of HHS) scheduling based on qualifications specified in the CSA. Congress may also consider whether placing additional synthetic drugs on Schedule I may hinder future medical research. In addition, policymakers may consider whether it is more efficient to place these drugs on Schedule I of the CSA or to treat them as analogue controlled substances under the Controlled Substances Analogue Enforcement Act. In considering enforcement challenges identified by the DEA, Congress may consider whether to amend the CSA to better facilitate enforcement action against the illicit synthetic drug market.", "type": "CRS Report", "typeId": "REPORTS", "active": true, "formats": [ { "format": "HTML", "encoding": "utf-8", "url": "http://www.crs.gov/Reports/R42066", "sha1": "23dd7f6beb13573a561c2593be6821293a136d2a", "filename": "files/20160226_R42066_23dd7f6beb13573a561c2593be6821293a136d2a.html", "images": null }, { "format": "PDF", "encoding": null, "url": "http://www.crs.gov/Reports/pdf/R42066", "sha1": "889b43da4e4aff2ed142d2a970f203ddebb4270c", "filename": "files/20160226_R42066_889b43da4e4aff2ed142d2a970f203ddebb4270c.pdf", "images": null } ], "topics": [ { "source": "IBCList", "id": 2496, "name": "Crime and Punishment" } ] }, { "source": "University of North Texas Libraries Government Documents Department", "sourceLink": "https://digital.library.unt.edu/ark:/67531/metadc817075/", "id": "R42066_2014Aug15", "date": "2014-08-15", "retrieved": "2016-03-19T13:57:26", "title": "Synthetic Drugs: Overview and Issues for Congress", "summary": null, "type": "CRS Report", "typeId": "REPORT", "active": false, "formats": [ { "format": "PDF", "filename": "files/20140815_R42066_118a8bcfbb70b8fd76fbae95c53d48518ef9d1c5.pdf" }, { "format": "HTML", "filename": "files/20140815_R42066_118a8bcfbb70b8fd76fbae95c53d48518ef9d1c5.html" } ], "topics": [] }, { "source": "University of North Texas Libraries Government Documents Department", "sourceLink": "https://digital.library.unt.edu/ark:/67531/metadc227736/", "id": "R42066_2013Sep16", "date": "2013-09-16", "retrieved": "2013-11-05T18:07:05", "title": "Synthetic Drugs: Overview and Issues for Congress", "summary": "This report discusses the federal scheduling of controlled substances, including the temporary scheduling of substances. It also provides an overview of current trends in selected synthetic cannabinoids and stimulants. It concludes with a review of relevant legislation as well as possible issues policymakers might consider.", "type": "CRS Report", "typeId": "REPORT", "active": false, "formats": [ { "format": "PDF", "filename": "files/20130916_R42066_2dd9215917ed4ba3baf42f030f02e3eb29b759ca.pdf" }, { "format": "HTML", "filename": "files/20130916_R42066_2dd9215917ed4ba3baf42f030f02e3eb29b759ca.html" } ], "topics": [ { "source": "LIV", "id": "Designer drugs", "name": "Designer drugs" }, { "source": "LIV", "id": "Synthetic fabrics", "name": "Synthetic fabrics" }, { "source": "LIV", "id": "Synthetic drugs of abuse", "name": "Synthetic drugs of abuse" }, { "source": "LIV", "id": "Narcotic laws", "name": "Narcotic laws" } ] }, { "source": "University of North Texas Libraries Government Documents Department", "sourceLink": "https://digital.library.unt.edu/ark:/67531/metadc83995/", "id": "R42066_2011Oct28", "date": "2011-10-28", "retrieved": "2012-04-27T15:49:45", "title": "Synthetic Drugs: Overview and Issues for Congress", "summary": "This report discusses the federal scheduling of controlled substances, including the temporary scheduling of substances. It also provides an overview of current trends in selected synthetic cannabinoids and stimulants. It concludes with a review of selected relevant legislation in the 112th Congress as well as issues for policymakers to consider.", "type": "CRS Report", "typeId": "REPORT", "active": false, "formats": [ { "format": "PDF", "filename": "files/20111028_R42066_5483f1cf37cc734944effebd1c0a595879d4325f.pdf" }, { "format": "HTML", "filename": "files/20111028_R42066_5483f1cf37cc734944effebd1c0a595879d4325f.html" } ], "topics": [ { "source": "LIV", "id": "Designer drugs", "name": "Designer drugs" }, { "source": "LIV", "id": "Synthetic fabrics", "name": "Synthetic fabrics" }, { "source": "LIV", "id": "Synthetic drugs of abuse", "name": "Synthetic drugs of abuse" }, { "source": "LIV", "id": "Narcotic laws", "name": "Narcotic laws" } ] } ], "topics": [ "Crime Policy", "Health Policy", "Intelligence and National Security" ] }